Evaluation of the Prevalence of Anti-transglutaminase 2 and 6 Antibodies in Patients with Sero-Positive Multiple Sclerosis.

Q3 Medicine Middle East Journal of Digestive Diseases Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI:10.34172/mejdd.2024.368

Mohammad Hassan Emami, Mohammad Reza Najafi, Sepideh Allahdadian, Samane Mohammadzadeh, Nahid Jamali, Anasik Lalazarian, Vahid Shaygan Nejad, Fatemeh Maghool

{"title":"Evaluation of the Prevalence of Anti-transglutaminase 2 and 6 Antibodies in Patients with Sero-Positive Multiple Sclerosis.","authors":"Mohammad Hassan Emami, Mohammad Reza Najafi, Sepideh Allahdadian, Samane Mohammadzadeh, Nahid Jamali, Anasik Lalazarian, Vahid Shaygan Nejad, Fatemeh Maghool","doi":"10.34172/mejdd.2024.368","DOIUrl":null,"url":null,"abstract":"Background: Gluten sensitivity (GS) is one of the gluten-related disorders (GRDs). Patients with GS may have serum antibodies against tissue transglutaminase (tTG) (IgA and IgG) without any evidence of enteropathy. We aimed to evaluate both tTG-6 and tTG-2 antibodies to determine the prevalence of seropositive tTG-2 and tTG-6 antibodies in patients with multiple sclerosis (MS).Methods: In this cross-sectional study, we carried out serological tests (IgA & IgG anti-tTG-6 and tTG-2 antibodies) in patients with MS.Results: Seventy-two patients with MS were included in this study. Of them, seropositive patients for total (IgA+IgG) of tTG-6 and tTG-2 autoantibodies were 9.7% (95% CI, 4.2-18) and 5.6% (95% CI, 1.4-12.5), respectively.Conclusion: Anti-tTG-6 antibody testing may be necessary for early diagnosis of GS in patients with MS. More studies with larger sample sizes are warranted to confirm these data.","PeriodicalId":18517,"journal":{"name":"Middle East Journal of Digestive Diseases","volume":"16 1","pages":"47-51"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264836/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Digestive Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/mejdd.2024.368","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gluten sensitivity (GS) is one of the gluten-related disorders (GRDs). Patients with GS may have serum antibodies against tissue transglutaminase (tTG) (IgA and IgG) without any evidence of enteropathy. We aimed to evaluate both tTG-6 and tTG-2 antibodies to determine the prevalence of seropositive tTG-2 and tTG-6 antibodies in patients with multiple sclerosis (MS).

Methods: In this cross-sectional study, we carried out serological tests (IgA & IgG anti-tTG-6 and tTG-2 antibodies) in patients with MS.

Results: Seventy-two patients with MS were included in this study. Of them, seropositive patients for total (IgA+IgG) of tTG-6 and tTG-2 autoantibodies were 9.7% (95% CI, 4.2-18) and 5.6% (95% CI, 1.4-12.5), respectively.

Conclusion: Anti-tTG-6 antibody testing may be necessary for early diagnosis of GS in patients with MS. More studies with larger sample sizes are warranted to confirm these data.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估血清阳性多发性硬化症患者中抗转谷氨酰胺酶 2 和 6 抗体的流行率

背景：麸质敏感症（GS）是麸质相关疾病（GRD）之一。麸质过敏症患者的血清中可能存在针对组织转谷氨酰胺酶（tTG）的抗体（IgA 和 IgG），但没有任何肠病的证据。我们旨在评估 tTG-6 和 tTG-2 抗体，以确定多发性硬化症（MS）患者血清中 tTG-2 和 tTG-6 抗体阳性的发生率：在这项横断面研究中，我们对多发性硬化症患者进行了血清学检测（抗tTG-6和tTG-2抗体的IgA和IgG）：结果：72 名多发性硬化症患者参与了这项研究。其中，tTG-6和tTG-2自身抗体总和（IgA+IgG）血清阳性患者分别为9.7%（95% CI，4.2-18）和5.6%（95% CI，1.4-12.5）：结论：抗-tTG-6抗体检测可能是早期诊断多发性硬化症患者GS的必要手段。需要更多样本量更大的研究来证实这些数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊